Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Gothenburg – page 17

376 clinical trials in Gothenburg, Sweden across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Gothenburg at a glance
376
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

376 trials in Gothenburg

Open in trial search

Small cell lung cancer limited stage

Not yet recruiting

Durvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Dementia Alzheimer's type

Not yet recruiting

A Phase 2 Study of TML-6 in Adults with Early Alzheimer’s Disease to Evaluate Safety, Tolerability, and Efficacy

Investigational
Countries:SwedenSweden
  • Participants:65+ years

Malignant melanoma stage IV+1

Not yet recruiting

Phase Ib/II study of momelotinib with nivolumab or pembrolizumab in unresectable stage III/IV cutaneous melanoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Karolinska University Hospital

Cardiac amyloidosis

Not yet recruiting

Efficacy and safety of eplontersen sodium plus ALXN2220 in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Alxn2220
  • Sponsor:AstraZeneca AB

Abortion induced

Not yet recruiting

Ropivacaine hydrochloride versus electrolytes for pain relief in women undergoing second‑trimester medical abortion after 13 weeks

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Mannitol
  • Sponsor:Karolinska Institutet

Colorectal cancer

Not yet recruiting

Conversion intraperitoneal chemotherapy with oxaliplatin plus drug combination in colorectal cancer with peritoneal metastases unsuitable for upfront surgery or HIPEC

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Uppsala University Hospital

Acute myeloid leukaemia

Not yet recruiting

A study of hydroxyurea added to standard drug combination to assess safety and effectiveness in adults with relapsed or refractory acute myeloid leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Karolinska University Hospital

Palliative care

Not yet recruiting

Morphine Hydrochloride for Resting Breathlessness in Adults with Serious Chronic Life‑Limiting Disease Receiving Palliative Care

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Region Skane

Alpha-1 antitrypsin deficiency

Not yet recruiting

Safety and Efficacy of TSRA-196 (rnaivt9315 and rnacs24757) in Adults with Lung or Liver Disease due to Alpha‑1 Antitrypsin Deficiency

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years

Parkinson's disease

Not yet recruiting

Montelukast Sodium for disease-modifying treatment in patients with mild‑moderate Parkinson’s disease: open‑label phase II extension study

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Montelukast Sodium
  • Sponsor:Karolinska University Hospital

Coronary artery disease

Not yet recruiting

Prognostic H2[15O] PET Imaging Study in Patients with Coronary Artery Disease Using O15‑Water, Adenosine and Regadenoson

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Adenosine
  • Sponsor:Vaestra Goetalandsregionen

Cystic fibrosis

Not yet recruiting

Safety and Efficacy of VX-828, Deutivacaftor, and Tezacaftor in Adults with Cystic Fibrosis

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Sponsor:Vertex Pharmaceuticals Inc.

Other cities in Sweden

The busiest research cities in the country

All 65 cities in Sweden

Clinical research in Gothenburg

What the registry says about research in the country

01 Oncology Research

Multiple clinical trials focusing on innovative treatments for various types of leukemia, including chronic lymphocytic leukemia and acute myeloid leukemia. Studies are evaluating new therapeutic combinations and treatment approaches for lymphoma and pediatric cancers.

  • Chronic Myeloid Leukemia Treatment
  • Pediatric Cancer Immunotherapy
  • Follicular Lymphoma Management

Advanced research into targeted therapies and personalized treatment protocols for better patient outcomes.

02 Rare Diseases

Groundbreaking studies on rare genetic conditions including Niemann-Pick disease and gangliosidoses. Research focuses on evaluating novel treatments and investigating long-term outcomes for mucopolysaccharidosis and other rare disorders.

  • Genetic Disorder Treatments
  • Enzyme Replacement Therapies
  • Rare Disease Management

Innovative approaches to addressing complex rare diseases with targeted therapeutic interventions.

03 Cardiovascular and Renal Studies

Comprehensive research into cardiovascular disease prevention and treatment, alongside studies on various kidney conditions. Trials evaluating new medications for stroke prevention in atrial fibrillation and treatments for glomerular diseases.

  • Stroke Prevention
  • Kidney Disease Therapies
  • Cardiovascular Risk Management

Focus on developing effective treatments for both common and rare cardiovascular and renal conditions.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.